Condition: IgAN - IgA Nephropathy · Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) · C3 Glomerulopathy (C3G) · Sponsor: Qilu Pharmaceutical Co., Ltd.
QLS7305 injection is a chemically synthesized double-stranded small interfering RNA (siRNA) targeting complement C3, covalently linked to a ligand containing N-acetylgalactosamine (GalNAc) residues. After subcutaneous (SC) administration, it can inhibit C3 synthesis through the RNA interference (RNAi) mechanism, reduce circulating C3 protein levels, decrease the generation of complement-activated C5 convertase, and inhibit complement pathway activation. It is expected to become an effective treatment for complement-mediated kidney diseases and hematological disorders.
This description comes directly from the study's public registry record.
Chuan Tian · 15801230857 · chuan2.tian@qilu-pharma.com
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07730632